# i01 strong-solver screen: raw returns (2026-10-18)

Three fresh blind-solver contexts (claude-opus-5-5, effort max), each given only the workspace root,
the packet path runs/i01-screen-155659c7335608d0/solver-1 and the exact sentence. Gold: $450.9 million.
Returns kept verbatim in substance (harness indentation removed), numbered in order of arrival.

## Solve 1: $450.9 million (right), confidence high

answer: $450.9 million

confidence: high. Fiscal Q4 2026 (Mar–May 2026) is not reported directly anywhere in the packet. I worked it out from the changes in the remaining buyback authorization, and every check I could run agrees with it.

path:
Paychex's fiscal year ends May 31 (D01 L18: "fiscal year ending May 31, 2027"). So the twelve months ended Aug 31, 2026 are fiscal Q2 2026 + Q3 2026 + Q4 2026 + fiscal Q1 2027.
1. Q2 FY2026 (Sep–Nov 2025) = $126.5M. D04 Part II Item 2 (text L1495-1498) shows "October 1, 2025 - October 31, 2025|1.0|122.54|126.5|$9.4" and Sept "$—" with $135.9 remaining. The three-month equity statement agrees (D04 L220, "(126.5)"), as does 286.6 (six months, D04 L314) − 160.1 (Q1 FY2026, D02 L218/L274) = 126.5.
2. Q3 FY2026 (Dec 2025–Feb 2026) = $75.0M. D06 Item 2 (L1525-1528): Dec "$—"; "January ... 0.5|102.59|50.0|$950.0"; "February ... 0.3|92.65|25.0|$925.0"; "Total ... $75.0|$925.0". The three-month equity statement agrees (D06 L220, "(75.0)"), as does 361.6 (nine months, D06 L316) − 286.6 = 75.0.
3. Program facts. D02 L228 / D06 L230: the $400.0M program "expired on January 16, 2026, at which time $9.4 million of unused repurchase authorization expired. On January 16, 2026, the Company's Board approved a program to repurchase up to an additional $1.0 billion ... with no expiration date." No other new authorization is mentioned anywhere.
4. Q1 FY2027 (Jun–Aug 2026) = $0. D02 Item 2 (L1404-1407): every month shows "—" bought, and "Total for the period|—|$—|$—|$675.6". The cash flow line is "Repurchases of common shares|—|(160.1)|" (D02 L274; D01 L272), and the equity statement line is also "—" (D02 L203).
5. Q4 FY2026 (Mar–May 2026) = $249.4M (derived). June had no purchases, so the $675.6M remaining at June 30 was also the balance at May 31, 2026. The remaining balance was $925.0M at Feb 28, 2026, so 925.0 − 675.6 = 249.4. The method is sound because the authorization column falls by exactly the dollars bought each month: 135.9 − 126.5 = 9.4; 1,000 − 50.0 = 950.0; 950.0 − 25.0 = 925.0. Share count is consistent: 358.3M at Feb 28 (D06 L209) fell to 355.6M at May 31 (D02 L198), down 2.7M net. $249.4M ÷ ~2.75M shares ≈ $91/share, which fits the February average of $92.65. The June-quarter cash flow shows no repurchase cash, so no late-May trades were left to settle.
6. Total: 126.5 + 75.0 + 249.4 + 0.0 = 450.9. Check (D02 + D04 only): old program used from Sep 1, 2025 until it expired = 135.9 − 9.4 = 126.5. New program used through Aug 31, 2026 = 1,000.0 − 675.6 = 324.4. 126.5 + 324.4 = 450.9. Check (D02 + D06 only): (361.6 − 160.1) + 249.4 + 0 = 201.5 + 249.4 = 450.9.

minimal_documents: {D02, D06}. Equivalent alternative: {D02, D04}. D02 cannot be replaced: it is the only source of the $675.6M balance at May 31 / Aug 31, 2026. D01 confirms the Q1 FY2027 zero but lacks that balance. {D02, D05} and {D02, D03} are not enough: neither gives the Feb 28 balance ($925.0M) or the Aug/Nov 2025 balances.

readings:
- Main reading: trailing twelve months, Sep 1, 2025–Aug 31, 2026: 450.9.
- Fiscal 2026 instead (twelve months ended May 31, 2026): 160.1 + 126.5 + 75.0 + 249.4 = 611.0. This is not the period the question asks about.
- Only directly reported quarters (leaving out the derived Mar–May quarter): 126.5 + 75.0 + 0 = 201.5. This is incomplete because Mar–May 2026 is part of the window.
- Cash-paid basis: the same 450.9, given no unsettled trades at May 31 (point 5).
- Excise tax: fiscal 2025 rows show "including excise taxes of $0.5 million", but fiscal 2026 rows mention none, and the Item 2 dollars equal the equity-statement amounts in Q2 and Q3. Any excise difference in Mar–May 2026 can't be determined, but none is suggested.

gaps:
- The packet has no fiscal 2026 10-K or Q4 FY2026 earnings release. The $249.4M for Mar–May 2026 is derived from "Approximate dollar value of shares that may yet be purchased". It assumes the authorization did not change between Feb 28 and Jun 30, 2026, which is supported by D02 naming only the Jan 16, 2026 program.
- A $135.9 figure in D02 (L472) is "Costs to fulfill contracts", unrelated to buybacks.
- Coverage: searched all six texts for repurchase, buyback, treasury, authorization, share-count and Q4/fiscal-2026 terms. Read all of D01. In D02, D04 and D06 read the equity statements, cash flows, MD&A financing sections and Part II Item 2. In D03 and D05 only the shareholder-return sections. Confirmed the key table rows in the docs/ source .txt files; there are no PDFs. Other sections of D02–D06 were not read.

contaminated: no. A question.txt appeared in a file listing; I did not open it. No answer or hint leaked.

## Solve 2: $450.9 million (right), confidence high

answer: $450.9 million

confidence: high

path:
The window is Sep 1, 2025 to Aug 31, 2026. Paychex's fiscal year ends May 31, so this covers Q2, Q3 and Q4 of FY2026 plus Q1 of FY2027. The packet has no FY2026 10-K, so Q4 FY2026 has to be worked out from the remaining buyback authorization.
1. Q2 FY2026 (Sep–Nov 2025) = 126.5. D04 three-month equity statement: "Repurchases of common shares (2)|(1.0)|(0.0)|(4.9)|(121.6)|...|(126.5)". D04 Part II Item 2: "October 1, 2025 - October 31, 2025|1.0|122.54|126.5|$9.4" (September and November: none). Cross-check: D04/D03 six months 286.6, minus D02/D01 Q1 FY2026 "(160.1)" = 126.5.
2. Q3 FY2026 (Dec 2025–Feb 2026) = 75.0. D06 three-month equity statement: "(0.8)|(0.0)|(3.7)|(71.3)|...|(75.0)". D06 Part II: "January ... 0.5|102.59|50.0|$950.0", "February ... 0.3|92.65|25.0|$925.0", "Total for the period|0.8|$99.05|$75.0|$925.0". Cross-check: D06 nine months "(361.6)" minus 286.6 = 75.0.
3. Program terms. D06/D02 footnote (2): the $400.0M program "expired on January 16, 2026, at which time $9.4 million of unused repurchase authorization expired. On January 16, 2026, the Company's Board approved a program to repurchase up to an additional $1.0 billion ... with no expiration date." No later authorization change is mentioned.
4. Q1 FY2027 (Jun–Aug 2026) = 0. D02/D01 cash flow: "Repurchases of common shares|—|(160.1)". D02 equity statement: "Repurchases of common shares (2)|—|...". D02 Part II: "June 1, 2026 - June 30, 2026|—|$—|$—|$675.6", and July, August and the period total are all 675.6.
5. Q4 FY2026 (Mar–May 2026). Remaining authorization was $925.0M at Feb 28, 2026 (D06). With no June purchases, it was $675.6M at May 31, 2026 (D02). So Q4 = 925.0 − 675.6 = 249.4.
6. Total = 126.5 + 75.0 + 249.4 + 0 = 450.9. Check via program usage: (135.9 Sep-2025 remaining [D04] − 9.4 expired) + (1,000.0 − 675.6) = 126.5 + 324.4 = 450.9. Check via cash flow: (361.6 − 160.1) + 249.4 = 450.9. Plausibility only: shares outstanding fell from 358.3M (Feb 28) to 355.6M (May 31), and APIC moved +10.2. Both fit roughly 2.8M shares bought at about $89 in Q4.
7. Excluded: Q1 FY2026's $160.1M (Jun–Aug 2025, before the window).

minimal_documents: D02 + D06. Q2+Q3 = 361.6 − 160.1 (D02's prior-year column); Q4 = 925.0 − 675.6; Q1 FY2027 = 0. Alternative: D02 + D04. Q2 = 126.5. D04 shows $9.4M left at Nov 30, 2025, and D02 says that $9.4M expired unused. The new $1.0B program had $675.6M left, so $324.4M was used, all in Jan–May 2026. Total 450.9. D02 cannot be swapped out. D01, D03 and D05 (earnings releases) have no remaining-authorization figures, so Q4 cannot be derived without D02.

readings:
- Fiscal-year misreading (Jun 2025–May 2026): 361.6 + 249.4 = 611.0. This is not the window asked about.
- Counting "Activity related to equity-based plans" (net employee-plan flows, e.g. −23.6 in Q1 FY2027) as repurchases: not supported by the labels, and the Q4 value is unknown. I reject this reading.
- Adding any excise tax on FY2026 repurchases: the documents disclose none for FY2026. Part II dollar totals equal the equity-statement repurchase lines for Q2 and Q3, so the answer stays 450.9.

gaps:
- No FY2026 10-K or Q4 FY2026 release is in the packet. Q4 is derived from the change in "Approximate dollar value of shares that may yet be purchased." This assumes no authorization change between Feb 28 and May 31, 2026 (none is mentioned) and that the "approximate" figures are exact to 0.1.
- The documents are text sources (no PDFs or layout files), so there were no page images to check.
- Coverage: D01 read in full. D02 lines 1–300, 340–345, 1090–1119 and 1155–1444. D04 lines 186–320 and 1480–1509. D06 lines 186–325 and 1510–1549. D05 lines 100–124. The rest of D02–D06 (and D03 entirely) was covered only by keyword searches. The decisive figures were also confirmed in the docs/ source files.

contaminated: no. question.txt appeared in a file listing but was not read.

## Solve 3: $450.9 million (right), confidence high

answer: $450.9 million

confidence: high

path:
Paychex's fiscal year ends May 31, so the twelve months ended Aug 31, 2026 are Q2 FY26 (Sep–Nov 2025), Q3 FY26 (Dec 2025–Feb 2026), Q4 FY26 (Mar–May 2026) and Q1 FY27 (Jun–Aug 2026). The packet has no FY2026 10-K, so Q4 FY26 has to be worked out from the remaining-authorization figures in the Part II Item 2 tables.
1. Q1 FY27 = $0. D02 (Q1 FY27 10-Q), equity statement line 203: "Repurchases of common shares (2)|—|…|—|". Cash flow line 274: "Repurchases of common shares|—|(160.1)|". D01 line 272 shows the same. D02 Part II lines 1404–1407 show no purchases in June, July or August 2026, with "$675.6" left in each month. So $675.6M was also left at May 31, 2026.
2. Q1 FY26 (comparative period) = $160.1M. D02 line 218: "Repurchases of common shares(2)|(1.1)|…|(160.1)|".
3. Nine months ended Feb 28, 2026 = $361.6M. D06 line 205: "…|(361.6)|". The D06 cash flow (line 316) and the D05 release (line 120, "Repurchased 2.9 million shares of our common stock for $361.6 million") agree.
4. Q3 FY26 = $75.0M. D06 line 220: "(75.0)". D06 Part II lines 1525–1528 show December "$—" with "$9.4" left; January "0.5|102.59|50.0|$950.0"; February "0.3|92.65|25.0|$925.0".
5. Q2 FY26 = $126.5M. D04 line 220: "(126.5)". D04 Part II line 1496: "October 1, 2025 - October 31, 2025|1.0|122.54|126.5|$9.4". Check: 361.6 − 160.1 − 75.0 = 126.5.
6. Programs (D02 line 228 / D06 line 230): the $400.0M program "expired on January 16, 2026, at which time $9.4 million of unused repurchase authorization expired. On January 16, 2026, the Company's Board approved a program to repurchase up to an additional $1.0 billion…". No other authorization change is mentioned.
7. Q4 FY26 = 925.0 − 675.6 = $249.4M (remaining authorization at Feb 28, 2026 minus remaining at May 31, 2026).
8. Total = 126.5 + 75.0 + 249.4 + 0 = 450.9. Equivalently (361.6 − 160.1) + 249.4 + 0 = 201.5 + 249.4 = 450.9. Second route by program: old-program use in the window = 135.9 (left after September 2025, which had no purchases; D04 line 1495) − 9.4 (expired unused) = 126.5. New-program use = 1,000.0 − 675.6 = 324.4. Total 126.5 + 324.4 = 450.9.
9. Plausibility check: shares outstanding fell from 358.3M (D06, Feb 28, 2026) to 355.6M (D02, May 31, 2026). That fits roughly 2.8–2.9M shares bought back at about $86–89, after the February average price of $92.65.

minimal_documents: {D02, D06}. Alternative: {D02, D04}, using the program route in step 8. D02 cannot be replaced: only it gives Q1 FY27 = 0 and the $675.6 figure. The releases (D01, D03, D05) have no authorization figures, so {D02, D03} and {D02, D05} cannot isolate Q4 FY26 or the Dec 2025–Jan 16, 2026 old-program activity.

readings:
- Counting only quarters directly reported in the packet (Q2, Q3 FY26 and Q1 FY27), leaving out the Q4 FY26 gap: $201.5M. This is incomplete, because Q4 is derivable.
- Reading the window as fiscal 2026 (Jun 2025–May 2026): 361.6 + 249.4 = $611.0M. This does not match the window asked for.
- The preferred answer remains $450.9M.

gaps:
- No FY2026 10-K or Q4 FY26 release is in the packet. Q4 FY26 ($249.4M) is derived from "approximate" remaining-authorization figures, not from a reported repurchase line.
- If the FY2026 annual statements put any excise tax into the full-year repurchase line (FY2025 lines said "including excise taxes of $0.5 million"; the FY2026 interim lines don't mention it), that figure could differ slightly from the purchase-dollar total. The packet gives no FY2026 excise-tax amount.
- Coverage: read all of D01. In D02 lines 1–330, 1085–1290 and 1380–1449. In D04, lines 186–275 and 1480–1509. In D05, lines 1–140. In D06, lines 180–329, 1362–1393 and 1505–1564. In D03, lines 112–129. Searched all six text files for repurchas, buyback/retire/excise/"may yet be purchased", "subsequent to", and authoriz/program, and checked the decisive rows against the docs/ originals: 675.6, 925.0, 950.0, 9.4 and 135.9 match. The other note sections of the 10-Qs were not read line by line.

contaminated: no
